Who
Michael Conick Hanley Jr.
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Alto Neuroscience; Chief Business Officer, Spyre Therapeutics.
In numbers
- Trades disclosed
- 17
- Buys
- 1
- Sells
- 0
- Bought
- $20K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 21 Oct 2019
- Last trade
- 11 Feb 2026
- Last filed
- 13 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Feb 2026filed 13 Feb 2026 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —131,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —131,000 at $0.00 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —8,000 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —188,000 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —188,000 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 | filing |
| 3 Jul 2025filed 8 Jul 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —125,000 | filing |
| 5 Feb 2025filed 7 Feb 2025 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 20 May 2024filed 22 May 2024 | ANRO Alto Neuroscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —188,000 at $0.00 | filing |
| 23 Feb 2023filed 24 Feb 2023 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 23 Aug 2022filed 25 Aug 2022 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 8 Jun 2022filed 10 Jun 2022 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Bought | $20K28,200 at $0.71 | filing |
| 17 Feb 2022filed 22 Feb 2022 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —160,000 at $0.00 | filing |
| 17 Feb 2021filed 19 Feb 2021 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 14 Feb 2020filed 19 Feb 2020 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 21 Oct 2019filed 23 Oct 2019 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
News
Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)SYRE · themarketsdaily.com · 19 Oct 2026Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026SYRE · manilatimes.net · 18 Oct 2026
0 headlines in the last 90 days name Michael Conick Hanley Jr.; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.